全文获取类型
收费全文 | 3652篇 |
免费 | 289篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 96篇 |
妇产科学 | 107篇 |
基础医学 | 316篇 |
口腔科学 | 81篇 |
临床医学 | 315篇 |
内科学 | 638篇 |
皮肤病学 | 120篇 |
神经病学 | 172篇 |
特种医学 | 180篇 |
外国民族医学 | 1篇 |
外科学 | 649篇 |
综合类 | 373篇 |
一般理论 | 2篇 |
预防医学 | 290篇 |
眼科学 | 37篇 |
药学 | 314篇 |
2篇 | |
中国医学 | 97篇 |
肿瘤学 | 174篇 |
出版年
2023年 | 25篇 |
2022年 | 110篇 |
2021年 | 145篇 |
2020年 | 89篇 |
2019年 | 80篇 |
2018年 | 129篇 |
2017年 | 96篇 |
2016年 | 97篇 |
2015年 | 142篇 |
2014年 | 152篇 |
2013年 | 200篇 |
2012年 | 295篇 |
2011年 | 303篇 |
2010年 | 198篇 |
2009年 | 175篇 |
2008年 | 202篇 |
2007年 | 169篇 |
2006年 | 196篇 |
2005年 | 169篇 |
2004年 | 137篇 |
2003年 | 120篇 |
2002年 | 120篇 |
2001年 | 85篇 |
2000年 | 56篇 |
1999年 | 56篇 |
1998年 | 38篇 |
1997年 | 28篇 |
1996年 | 33篇 |
1995年 | 17篇 |
1994年 | 15篇 |
1993年 | 31篇 |
1992年 | 28篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 29篇 |
1988年 | 19篇 |
1987年 | 21篇 |
1986年 | 27篇 |
1985年 | 9篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 11篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 10篇 |
1971年 | 6篇 |
排序方式: 共有4004条查询结果,搜索用时 15 毫秒
1.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。 相似文献
2.
Nozha Brahmi Youssef Blel Nadia Kouraichi Salma Lahdhiri Hafedh Thabet Abderrazek Hedhili Mouldi Amamou 《Journal of infection and chemotherapy》2006,12(4):190-194
The present study included three periods: (1) a 12-month prerestriction and control period in 2001; (2) a 12-month restriction
period with reduced ceftazidime prescribing in favor of piperacillin-tazobactam (2002); (3) and a 24 month postrestriction
period (2003–2004). Note that, for results, P represents the difference between 2002 and 2001; P′, the difference between 2003 and 2001; and P″, the difference between 2004 and 2001. No changes in hygiene practices were observed during these three periods. The purpose
of this study was to assess the effect of reducing ceftazidime use in an intensive care unit (ICU) upon Gram-negative bacterial
resistance, particularly as regards Pseudomonas aeruginosa. During the three periods of the study, patients were similar concerning age, Simplified Acute Physiology Score (SAPSII),
the site of nosocomial infection, and the requirements for mechanical ventilation (75% in 2001, 76% in 2002, 74% in 2003,
and 85% in 2004). The most commonly isolated pathogens were P. aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. The use of ceftazidime decreased significantly from 12.6% in 2001 to 9% in 2002, to 3% in 2003 (P′ = 0.0009), and 2.6% in 2004 (P″ = 0.0001) in favor of piperacillin-tazobactam (0% 2001 to 3.7% in 2003; P′ = 0.002; and 5% in 2004; P″ = 0.0001). Simultaneously, we observed a significant decrease in isolates of P. aeruginosa resistant to piperacillin-tazobactam (P = 0.03; P′ = 0.004; P″ = 0.009), and those resistant to imipenem in 2003 (P′ = 0.008). We also noted a significant decrease in A. baumannii isolates resistant to ceftazidime (P′ = 0.01; P″ = 0.0004) and those resistant to imipenem in both 2002 and 2004 (P = 0.03; P″ = 0.04), and a considerable decrease in isolates of Klebsiella pneumoniae producing expanded spectrum betalactamase (ESBL) in 2003 and 2004 (P′ = 0.04; P″ = 6.10−5). In contrast, we noted an increase in penicillinase-producing isolates of K. pneumoniae, from 6% in 2001 to 16% in 2002 (p = 0.01), 20% in 2003 (P′ = 0.001), and 32% in 2004 (P″ = 10−6). We concluded that restriction of ceftazidime use was demonstrated to be efficient in reducing antimicrobial resistance,
especially to K. pneumoniae ESBL. 相似文献
3.
Elhaji Youssef A.; Stoica Ileana; Dennis Sheldon; Purisima Enrico O.; Lumbroso Rose; Beitel Lenore K.; Trifiro Mark A. 《Human molecular genetics》2006,15(9):1561
Human Molecular Genetics (2006) 15, 921931; 相似文献
4.
目的 观察优克龙 (Urocalun )治疗输尿管结石的疗效和安全性。 方法 对 6 0例输尿管结石直径 <1cm的患者予口服优克龙治疗 ,4 5 0mg/次 ,3次 /d ,服药 5周。 结果 6 0例患者中结石排出 4 5例 (75 % ) ;10例 (17% )结石位置下降 ;5例 (8% )位置无变化。 4例患者服药后有轻度胃部不适、恶心或口干。 结论 优克龙治疗输尿管结石效果良好。 相似文献
5.
6.
Chong-Sheng Chen Youssef Jounaidi David J Waxman 《Drug metabolism and disposition》2005,33(9):1261-1267
The anticancer prodrug ifosfamide (IFA) contains a chiral phosphorous atom and is administered in the clinic as a racemic mixture of R-IFA and S-IFA. Hepatic cytochrome P450 (P450) enzymes exhibit enantioselective preferences in the metabolism of R-IFA and S-IFA; however, the impact of this selectivity on P450-dependent anticancer activity is not known. Presently, the metabolism and cytotoxicity of R-IFA and S-IFA were determined in 9L gliosarcoma and Chinese hamster ovary tumor cells expressing an IFA-activating P450 enzyme and by in vitro steady-state kinetic analysis using cDNA-expressed P450 enzymes. Tumor cells expressing P450 enzyme CYP3A4 were the most sensitive to R-IFA cytotoxicity, whereas tumor cells expressing CYP2B1 or CYP2B6 were most sensitive to cyclophosphamide (CPA), an isomer of IFA. Correspondingly, CYP3A4-expressing cells and cDNA-expressed CYP3A4 metabolized R-IFA to yield the active, 4-hydroxylated metabolite at a 2- to 3-fold higher rate than they metabolized S-IFA or CPA. CYP2B cells and cDNA-expressed CYP2B enzymes metabolized CPA almost exclusively by 4-hydroxylation, whereas R-IFA and S-IFA were substantially converted to inactive, N-dechloroethylated metabolites. Further investigation revealed that CYP3A1, a rat enzyme, exhibited superior kinetic properties compared with the human enzyme CYP3A4, with R-IFA and S-IFA both metabolized with high catalytic efficiency by 4-hydroxylation and with a K(m) value of 200 microM, approximately 5-fold lower than CYP3A4. Based on these kinetic parameters and metabolic profiles, R-IFA is expected to exert greater anticancer activity than S-IFA or CPA against tumors that express CYP3A enzymes, whereas tumors expressing CYP2B enzymes may be more sensitive to CPA treatment. 相似文献
7.
8.
目的 通过彩色多普勒超声心动图 (CDUCG)和核磁共振成像 (MRI)诊断主动脉夹层动脉瘤 (AD)的影像学特征 ,比较两种无创检查技术诊断AD的临床价值。方法 对临床疑诊AD的患者行CDUCG心脏各切面探查 ,重点扫查并测量主动脉各节段异常超声征象 (夹层发生部位、内膜片跨度、管径宽度等 ) ,对相同患者行MRI检查时在扫描图像上辨认并确定夹层发生的部位、撕裂范围等。结果 CDUCG诊断Ⅰ型AD 4例 ,Ⅱ型 2例 ,Ⅲ型AD 1例。MRI对Ⅰ、Ⅱ、Ⅲ型AD均可明确诊断。本文 3例Ⅲ型AD经MRI确诊并检出附壁血栓 2例 ,1例Ⅰ型AD可疑 ,余结果同CDUCG。结论 两种技术诊断AD各有优缺点 ,CDUCG偏重于诊断Ⅰ、Ⅱ型 ,MRI适合各型AD的诊断。前者更为迅速、直观 ,重复性强 ,可了解心血管病变的全部信息 ;危急重症患者不宜或难以接受MRI检查。 相似文献
9.
Bayrak S; Holmdahl R; Travers P; Lauster R; Hesse M; Dolling R; Mitchison NA 《International immunology》1997,9(11):1687-1699
Type II collagen (CII) is of immunological interest because of its
repetitive structure and properties as an autoantigen. The mouse gene has
recently been cloned, thus enabling T cell-defined epitopes to be
identified. Multiple novel epitopes on mouse CII are here detected in the
autoreactive T cell response. The major response is directed to an epitope
with residues 707-721 located on the CB10 fragment. Some 25 other epitopes
are also recognized, including the autologous homologue of the 256-270
epitope which dominates in the response to foreign collagen. The cells
reactive with mouse collagen peptides were of Th1 type, as judged by
release of IFN-gamma. No significant reactivity was detected to mouse CII
peptides during ongoing disease. Alignment of the mouse epitopes revealed a
sequence motif with characteristic side chains at residues P1, P4 and P7,
and to a lesser extent at P5, within a nonamer core sequence. Binding of
these epitopes was simulated in a computer model of the I-Aq molecule,
where peptides with anchor residues at P1, P4 and P7 were indeed found to
fit the binding groove best. The spacing of pockets and the fine structure
of the binding surface of the I-Aq molecule meshes with the repetitive
structure of the collagen (X-Y-Gly), thus providing a likely explanation
for the occurrence of multiple epitopes. Comparison with human DR binding
motifs showed that the I-Aq motif resembles most closely that of the DR4
subtypes which predispose for rheumatoid arthritis.
相似文献
10.